Education
About Us
Working with TipRanks
Follow Us
Biomerica Inc (BMRA)
NASDAQ:BMRA
BMRA Stock Chart & Stats
$2.88
-$0.02(-5.81%)
At close: 4:00 PM EST
$2.88
-$0.02(-5.81%)
Day’s Range― - ―
52-Week Range$1.87 - $5.92
Previous CloseN/A
Volume74.49K
Average Volume (3M)190.48K
Market Cap
$6.73M
Enterprise Value$4.32M
Total Cash (Recent Filing)$2.54M
Total Debt (Recent Filing)$284.00K
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Apr 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding3,020,067
10 Day Avg. Volume453,881
30 Day Avg. Volume190,481
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.71
Price to Sales (P/S)1.32
P/FCF Ratio-1.81
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit17.30
Enterprise Value/Ebitda-1.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low absolute debt and a debt-to-equity of ~0.07 give the company durable financial flexibility. Over a 2–6 month horizon this reduces bankruptcy risk, lowers fixed financing burdens, and preserves optionality to raise capital or invest incrementally in commercialization or R&D when needed.
Improving Cash-burn TrendOperating and free cash flow losses have steadily narrowed, indicating management is reducing burn and improving operational efficiency. This trend, if sustained, lengthens runway and makes reaching break-even more attainable without immediate large capital raises, supporting medium-term viability.
Established Diagnostics Business ModelA core business selling in vitro diagnostic kits through direct and distributor channels creates recurring product revenue and diverse customer access. Combined with ongoing R&D on assays, this structural model supports steady demand and commercialization pathways that can scale with new assays over months.
Bears Say
Declining Revenue And Weak MarginsFalling revenue and very low gross margins mean the company struggles to cover fixed costs and achieve operating leverage. Persistent negative net margins limit reinvestment capacity and make sustainable profitability unlikely without revenue recovery or margin expansion over the medium term.
Persistent Negative Cash FlowOngoing cash outflows require external financing to sustain operations, which can lead to dilution or higher funding costs. Continued negative FCF constrains R&D, commercialization spend, and inventory support, raising execution risk and limiting ability to scale in the next several months.
Equity Erosion And Negative ROEMaterial decline in shareholder equity and deeply negative ROE reflect ongoing value destruction. This weakens the balance sheet cushion, may limit access to non-dilutive financing, and reduces strategic flexibility for investments or partnerships over a 2–6 month window.
Biomerica News
BMRA FAQ
What was Biomerica Inc’s price range in the past 12 months?
Biomerica Inc lowest stock price was $1.87 and its highest was $5.92 in the past 12 months.
What is Biomerica Inc’s market cap?
Biomerica Inc’s market cap is $6.73M.
When is Biomerica Inc’s upcoming earnings report date?
Biomerica Inc’s upcoming earnings report date is Apr 09, 2026 which is in 29 days.
How were Biomerica Inc’s earnings last quarter?
Biomerica Inc released its earnings results on Jan 14, 2026. The company reported -$0.454 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.454.
Is Biomerica Inc overvalued?
According to Wall Street analysts Biomerica Inc’s price is currently Overvalued.
Does Biomerica Inc pay dividends?
Biomerica Inc does not currently pay dividends.
What is Biomerica Inc’s EPS estimate?
Biomerica Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomerica Inc have?
Biomerica Inc has 3,020,067 shares outstanding.
What happened to Biomerica Inc’s price movement after its last earnings report?
Biomerica Inc reported an EPS of -$0.454 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.557%.
Which hedge fund is a major shareholder of Biomerica Inc?
Currently, no hedge funds are holding shares in BMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biomerica Inc
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Technical Analysis
Strata Skin Sciences
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
―
Ownership Overview
13.49% Insiders
6.82% Mutual Funds
0.61% Other Institutional Investors
78.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---